Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608555 | 0.92 | LMNA (0.45) | LMNAKMT2AMMP12MMP9TNF | |
| SCHEMBL23626685 | 0.90 | LMNA (0.44) | LMNAKMT2AMMP12MMP9TNF | |
| SCHEMBL30608556 | 0.90 | LMNA (0.44) | LMNAKMT2AMMP12MMP9TNF | |
| SCHEMBL1737629 | 0.86 | LMNA (0.55) | LMNAKMT2AMMP12MMP9TNF | |
| SCHEMBL13163903 | 0.86 | PRKCA (0.47) | LMNAMMP12MMP9TNFTSHR | |
| SCHEMBL14402257 | 0.85 | LMNA (0.42) | LMNAKMT2ATNFTSHRCASP3 | |
| SCHEMBL16774592 | 0.85 | TNF (0.45) | TNFMDM4TP53CASP3 | |
| SCHEMBL13904007 | 0.83 | PRKCA (0.45) | LMNAMMP12MMP9TNFTSHR | |
| SCHEMBL15976230 | 0.83 | TNF (0.46) | TNFMDM4TP53CASP3MDM2 | |
| SCHEMBL16244990 | 0.82 | LMNA (0.54) | LMNAKMT2AMMP12MMP9TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210205349-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2021-07-08 | — | — | US | disclosed |
| US-20060105948-A1 | GLP-2 derivatives | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105948-A1 | GLP-2 derivatives | GLP1R, GIPR, IAPP | LMNA 3366/4885KMT2A 3919/4885MMP12 4112/4885 |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | NGLY1, GALNT1, GALNT10 | LMNA 2369/4885KMT2A 4129/4885MMP12 4233/4885 |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | NGLY1, GALNT1, GALNT10 | LMNA 2401/4885KMT2A 3992/4885MMP12 4309/4885 |
| US-20210205349-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | NGLY1, GALNT1, GALNT10 | LMNA 2369/4885KMT2A 4129/4885MMP12 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.